Die 2$ dürfte nächste Woche fallen .Das Potential ist enorm deshalb wird Raptor kein kurzfristiges Investment sein .
Raptor has a high quality, experienced management team that has seen two drugs go through the arduous clinical process to commercialization at a previous company .The Company’s CEO, Christopher M. Starr, Ph.D., was a founder of BioMarin Pharmaceutical Inc. and saw both Aldurazyme and Naglazyme go from preclinical studies to market approval and commercialization. Aldurazyme, BioMarin’s first approved drug, had revenues of $151.3 million in 2008 (net $72.5 million to BioMarin based on their partnership with Genzyme).Naglazyme, BioMarin’s second approved drug,had revenues of $132.7 million in 2008.BioMarin is currently a multi-billion dollar market cap company and we believe that Dr. Starr and his management and scientific team, most of them originally from BioMarin, can do it again with Raptor Pharmaceuticals Corp.